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Abstract
This study aims to quantify the aggregate potential life-years (LYs) saved and healthcare cost-
savings if the Healthy People 2020 objective were met to reduce invasive colorectal cancer (CRC) 
incidence by 15%. We identified patients (n = 886,380) diagnosed with invasive CRC between 
2001 and 2011 from a nationally representative cancer dataset. We stratified these patients by sex, 
race/ethnicity, and age. Using these data and data from the 2001–2011 U.S. life tables, we 
estimated a survival function for each CRC group and the corresponding reference group and 
computed per-person LYs saved. We estimated per-person annual healthcare cost-savings using the 
2008–2012 Medical Expenditure Panel Survey. We calculated aggregate LYs saved and cost-
savings by multiplying the reduced number of CRC patients by the per-person LYs saved and 
lifetime healthcare cost-savings, respectively. We estimated an aggregate of 84,569 and 64,924 
LYs saved for men and women, respectively, accounting for healthcare cost-savings of $329.3 and 
$294.2 million (in 2013$), respectively. Per person, we estimated 6.3 potential LYs saved related 
to those who developed CRC for both men and women, and healthcare cost-savings of $24,000 for 
men and $28,000 for women. Non-Hispanic whites and those aged 60–64 had the highest 
aggregate potential LYs saved and cost-savings. Achieving the HP2020 objective of reducing 
invasive CRC incidence by 15% by year 2020 would potentially save nearly 150,000 life-years and 
$624 million on healthcare costs.
☆Disclaimer: The findings and conclusions in this paper are those of authors and do not necessarily represent the official position of 
the Centers for Disease Control and Prevention.
*Corresponding author at: Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford 
Highway, Chamblee Bldg. 107, MS F-76, Floor 3, Room 250, Chamblee, GA 30341, United States. dce3@cdc.gov (D.U. Ekwueme). 
Conflict of interest/financial disclosures
The authors disclose no conflict of interest. The authors reported no financial disclosures.
Transparency document
The http://dx.doi.org/10.1016/j.ypmed.2017.09.022 associated with this article can be found, in the online version.
HHS Public Access
Author manuscript
Prev Med. Author manuscript; available in PMC 2018 March 29.
Published in final edited form as:
Prev Med. 2018 January ; 106: 38–44. doi:10.1016/j.ypmed.2017.09.022.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Life years (LYs); Lifetime healthcare costs; Invasive colorectal cancer; Healthy People 2020
1. Introduction
Of cancers that affect both men and women, colorectal cancer (CRC) is the second leading 
cause of cancer-related deaths in the United States and the third most common cancer in 
men and in women (CDC, 2017a,b). The Healthy People 2020 (HP2020) agenda for 
improving the health of all Americans established the following objectives for colorectal 
cancer: 1) reduce the CRC death rate, 2) reduce the rate of invasive CRC, and 3) increase the 
proportion of adults who receive CRC screening based on current recommendations 
(HP2020, 2014).
A recent study from the Centers for Disease Control and Prevention (CDC) showed that 
while overall CRC test use increased from 2000 to 2015, the nation still had not reached the 
HP2020 target for increasing CRC screening (White et al., 2017). Weir and colleagues used 
mortality data from the CDC’s National Vital Statistics System (NVSS, 2016) to predict a 
reduction of 22.5% in CRC death rate from 2007 to 2020 and that the HP2020 target for 
reducing the CRC death rate would be met in 2013 (Weir et al., 2015). The target for the 
United States was met in 2014 (HP2020HP2014) and when examined by state, 30 states had 
achieved the HP2020 target to reduce invasive CRC incidence rates (Henley et al., 2017).
Given the mixed progress in meeting HP2020 CRC objectives for increasing CRC screening 
and reducing CRC death rates, we aim to focus on the HP2020 CRC objective of reducing 
the invasive CRC incidence rate from a baseline (year 2007) of 46.9/100,000 population to a 
target of 39.9/100,000 population in 2020 (HP2020HP2014), representing a 15% reduction 
over 10 years. We estimate the potential life-years (LYs) saved (health benefit) and lifetime 
healthcare cost-savings if this objective of reducing 15% of the invasive CRC incidence rate 
in 2007 were met by 2020. The purpose of this study is to provide federal, state, and local 
health policy-makers with potential quantifiable benefits that could occur if effective 
evidence-based interventions are implemented to achieve this objective. To our knowledge, 
this study is the first to quantify the health and economic benefits of achieving the HP2020 
CRC objective for reducing invasive CRC incidence rates.
2. Methods
2.1. Dataset for the estimation of the survival functions for CRC patients
We used the United States Cancer Statistics (USCS) data from the CDC’s National Program 
of Cancer Registries (NPCR) and the National Cancer Institute’s Surveillance, 
Epidemiology, and End Results (SEER) program, which together cover the cancer incidence 
for the entire U.S. population (CDC, 2016a,b; NCI, 2014). Both NPCR and SEER registries 
collect detailed patient information, including sex, race/ethnicity, year of diagnosis, age of 
diagnosis, cancer site, stage, survival months, histology, and vital status (CDC, 2016a,b; 
NCI, 2014). In 2014, the USCS provided data on survival for 62.8% of the U.S. population 
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(32 central cancer registries). From USCS, we identified a total of 886,380 patients who had 
been diagnosed with primary invasive CRC between 2001 and 2011, according to the 
International Classification of Disease for Oncology, 3rd Edition (ICD-O-3) site codes of 
C180–189, C209, and C260, with exclusion of patients with mesothelioma (histology codes 
of 9050–9055), kaposi sarcoma (9140), and lymphomas and leukemia (9590–9992). The 
CRC patients were followed through December 31, 2012 with a follow-up between 12 and 
144 months. Patients who had not died on this date were censored. The CRC patients were 
stratified by sex, race/ethnicity, and age.
2.2. Per-person potential LYs saved
For each group of the CRC patients, we used the Kaplan-Meier method to estimate a 
survival function for the 144 months following diagnosis (the longest follow-up with 
available data). We then extrapolated the survival function up to 600 months, using a semi-
parametric method (Hwang and Wang, 1999) (Fig. 1). 600 months was chosen, because 
these CRC patients’ survival probability approximates to zero at 600 months. The technical 
details for the extrapolation process has been described elsewhere (Chu et al., 2008; Fang et 
al., 2007; Hung et al., 2014; Liu et al., 2013). Briefly, this method used the data from the 
2001–2011 U.S. life tables of the general population (CDC, 2015) as a reference population. 
Using the same stratification as the stratification in CRC patients, we generated a survival 
function for each reference group corresponding to each group of the CRC patients. For each 
CRC-reference group, we fitted a linear regression to the logit transformed survival ratios 
(survival probabilities of the CRC group to those of the corresponding reference group) for 
the last 24 months of the 144 months of follow-up. Assuming a constant excess hazard 
(Andersson et al., 2013; Fang et al., 2007), we extrapolated the logit transformed survival 
ratios to 600 months and thus the survival function for each CRC group beyond the 144 
months to 600 months.
Based on the estimated survival functions for the CRC and the reference groups, we derived 
life expectancies (LEs) for each CRC group and the corresponding reference group. We then 
computed per-person potential LYs saved by subtracting LE for each reference group from 
that for the corresponding CRC group (Fig. 1).
2.3. Dataset for the estimation of the annual healthcare costs associated with CRC
We used data from the Medical Expenditure Panel Survey (MEPS) Household Component 
to estimate costs associated with CRC. The MEPS is a nationally representative survey that 
estimates healthcare use, expenditures, sources of payment, and insurance coverage for the 
U.S. civilian non-institutionalized population (AHRQ, 2015a). We pooled data from 2008 to 
2012, which comprised 177,054 people, including 587 individuals who reported that they 
were ever diagnosed with CRC. Annual healthcare expenditures in the MEPS are defined by 
the sum of the total annual healthcare costs paid via any type of payment (out-of-pocket, 
private insurance, Medicare, Medicaid, and other sources) for any service (ambulatory care, 
inpatient care, prescription medications, home health care, nursing home care, and other 
services) in a year (AHRQ, 2015a). We adjusted all costs to the 2013 price level using the 
Personal Health Care Expenditure Price Index (AHQR, 2015a,b).
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2.4. Per-person annual healthcare cost associated with CRC
We used a two-part model to estimate per-person annual healthcare cost associated with 
CRC, because the distribution of the cost data was right-skewed with 22% of the individuals 
with zero expenditure (Manning and Mullahy, 2001). In the first part, we used a logit model 
to predict the probability of any healthcare utilization; in the second part, we estimated 
utilization among those with positive expenditures using a generalized linear model with 
log-link and gamma-variance function. The covariates in this two-part model included CRC 
diagnosis (yes/no), sex, race/ethnicity, age, education, marital status, number of comorbid 
conditions, health insurance, and U.S. Census region. Based on the results, we predicted the 
average per-person annual healthcare costs associated with CRC for each of the sex, racial/
ethnic, and age groups.
2.5. Per-person lifetime healthcare cost-savings
For each group, we defined per-person lifetime cost-savings as the total cost saved, had a 
CRC patient not developed CRC. We used the following equation to calculate the mean per-
person lifetime cost-savings (E).
where t is time following CRC diagnosis, S(t) is the survival function for CRC patients 
(previously derived in Section 2.2), and C(t) is a smoothed function of healthcare cost 
associated with CRC in present value, based on the predicted annual healthcare costs 
associated with CRC (Section 2.4). Present values were calculated using an annual rate of 
3% (Gold et al., 1996) (Fig. 2).
2.6. Aggregate potential LYs saved and the corresponding healthcare cost-savings
We assumed that the HP2020 objective of a 15% reduction in the 2007 CRC incidence rate 
in 2020 is the same for each group. We computed the expected reduction in the number of 
CRC patients for each group by multiplying the 15% reduction in age-adjusted incidence 
rate in 2007 by the projected 2020 population for each group (USCB, 2012).
We calculated the aggregate potential LYs saved for each group by multiplying the expected 
reduction in the number of CRC patients by the potential per-person LYs saved. We 
calculated the aggregate healthcare cost-savings for each group by multiplying the expected 
reduction in the number of CRC patients by the estimated per-person lifetime cost-savings.
2.7. Statistical analysis
We adjusted for the complex sampling design in the MEPS following the analytic guidelines 
(AHRQ, 2014). We examined differences in per-person potential LYs saved and lifetime 
cost-savings between groups using a two-sided Z-test at the 0.05 level.
We used SAS 9.3 (SAS Institute Inc., Cary, NC) and STATA 13.1 (StataCorp LP, College 
Station, TX) for analyses. We estimated LE, per-person potential LYs saved, and per-person 
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lifetime cost-savings using the Integration of Survival with Quality of Life (iSQoL) 
statistical package (http://www.stat.sinica.edu.tw/isqol/).
All of the results are presented by men and women; non-Hispanic whites (NHW), non-
Hispanic blacks (NHB), and Hispanics; and age groups 50–54, 55–59, 60–64, 65–69, 70–74, 
75–79 and ≥80 years. The latter two age groups are not reported in the Results section (but 
are included in the tables), because regular CRC screening is not recommended for persons 
aged ≥75 years. We do not present groups whose incidence rates in 2007 were lower than the 
HP2020 target objective of 39.9/100,000 population (HP2020, 2014): American Indians or 
Alaska Natives, Asian/Pacific Islanders, and people aged < 50 years.
3. Results
3.1. Population characteristics
Table 1 presents the characteristics of CRC patients from NPCR/ SEER and the MEPS 
sample, stratified by sex, race/ethnicity, and age. For the 886,380 patients diagnosed with 
CRC between 2001 and 2011 (Table 1, upper panel), mean age at diagnosis was 66.7 years 
for men and 69.3 years for women; 69.2 years for NHW, 64.3 years for NHB, and 63.3 years 
for Hispanics. During follow-up, 402,501 (45.4%) patients died. Mean survival for patients 
who died was 24.5 months for men and 23.8 months for women; 24.6 months for NHW, 
21.5 months for NHB, and 23.4 months for Hispanics. Mean survival was 26.0, 25.3, 25.0, 
26.1, and 26.1 months for age group 50–54, 55–59, 60–64, 65–69, and 70–74, for patients 
who died during follow-up.
For the general population estimated from the 2008–2012 MEPS (Table 1, lower panel), 
mean age at survey of individuals with CRC was 70.0 years for men and 71.2 years for 
women; 70.8 years for NHW, 63.0 years for NHB, and 64.0 years for Hispanics. Mean 
annual healthcare costs were higher for men ($17,304) than women ($13,483) and for NHW 
($17,079) than Hispanics ($9551) and lowest for NHB ($7026). For age groups, mean 
annual healthcare costs ranged from $10,705 (age 50–54) to $21,042 (age 55–59).
3.2. Expected reduction in CRC patients, potential per-person LYs saved and aggregate 
potential LYs saved in the population
If the HP2020 objective of reducing invasive CRC incidence rate by 15% were met, we 
estimated a reduction of 13,473 cases in men and 10,348 cases in women between 2007 and 
2020 (Table 2); by race/ ethnicity, we estimated a reduction of 13,872 cases in NHW, 3515 
cases in NHB, and 3894 cases in Hispanics.
For each cancer averted, the estimated potential LYs saved for those who developed CRC 
was 6.3 years for both men and women; 6.1 years for NHW, 7.8 years for NHB, and 8.6 
years for Hispanics (p < 0.05). The estimated potential LYs saved ranged from 9.3 years for 
adults aged 50–54 years to 4.7 years for adults aged 70–74 years. The estimated aggregate 
potential LYs saved was 84,569 years for men and 64,924 years for women, i.e., ~150,000 
years for the entire population; 84,002 years for NHW, 27,260 years for NHB, and 33,380 
years for Hispanics (Table 2). The aggregate potential LYs saved ranged from 16,292 years 
for adults aged 50–54 years to 25,482 years for adults aged 60–64 years.
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3.3. Per-person lifetime healthcare cost-savings and aggregate healthcare cost-saving 
associated with CRC
The estimated lifetime cost-savings for each CRC case prevented were $24,000 (standard 
error, SE = $24) for men and $28,000 (SE = $30) for women (p < 0.05) (Table 3); $27,000 
for NHW (SE = $23), $23,000 (SE = $42) for NHB, and $26,000 (SE = $47) for Hispanics 
(p < 0.05). The estimated per-person lifetime cost-savings ranged from $28,000 for adults 
aged 70–74 years to $46,000 for adults aged 50–54 years. Aggregate healthcare cost-savings 
were $329.3 million for men and $294.2 million for women, i.e., ~$624 million for the 
entire population; $371.2 million for NHW, $80.8 million for NHB, and $102.5 million for 
Hispanics. Aggregate savings ranged from $79.8 million for age group 50–54 to $143.9 
million for age group 60–64.
4. Discussion
This study provides estimates of potential LYs saved and lifetime cost-savings at per-person 
and aggregate levels, if the HP2020 objective for a 15% reduction in invasive CRC incidence 
rates by year 2020 were met. We found that (1) per-person LYs saved was similar for men 
and women, but per-person lifetime cost-savings were higher for women than men; the 
aggregate LYs saved and aggregate cost-savings were larger for men than women; (2) per-
person LYs saved was the highest for Hispanics, followed by NHB and NHW, while per-
person lifetime cost-savings, aggregate LYs saved, and aggregate cost-savings were the 
highest for NHW, followed by Hispanics and NHB; (3) both per-person LYs saved and 
lifetime cost-savings decreased with age, while adults aged 60–64 years had the highest 
aggregate potential LY saved and aggregate lifetime costs-savings; and (4) overall achieving 
this objective would save ~150,000 LYs and $624 million on healthcare costs.
We note that the inconsistency between the per-person and the aggregate estimates when 
comparing between groups can be attributed to the expected reduction in the number of CRC 
cases for each group, resulting from the reduction in the incidence rate in 2007 and the 
projected 2020 population size for each group. When comparing LYs saved between men 
and women, the inconsistency (i.e., per-person potential LYs saved: men ≈ women, but 
aggregate potential LYs saved: men > women) results from the much higher incidence rate 
for men than women, dominating the effect of the larger size of the projected 2020 female 
population, and therefore a 15% reduction in the baseline incidence rate resulting in a much 
higher expected reduction in the number of CRC cases for men. When comparing potential 
LYs saved between racial/ethnic groups, the inconsistency (i.e., per-person potential LYs 
saved: Hispanic > NHB > NHW, while aggregate potential LYs saved: NHW > Hispanics > 
NHB) results from a much larger size of the projected 2020 NHW population than the 
higher incidence rate for NHB. The same rationale can be applied to the comparison 
between age groups and extended to explain the inconsistency in the per-person and the 
aggregate healthcare cost-savings between groups.
Similar to our study, Liu and colleagues found, using SEER registry data, that the expected 
years of life lost for CRC patients in comparison with the reference population was 6.5 
years. (Liu et al., 2013); in our study, the estimated potential LYs saved was 6.3 years for 
both men and women, if the incidence rates of CRC were reduced by 15%. Using the linked 
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SEER-Medicare dataset, 1996–2002, Lang et al. (2009) showed that excess CRC-related 
healthcare costs (defined as the difference in costs between CRC and the matched 
comparison patients, similar to our study) were $28,626 (in 2006$, $33,079 in 2013$) for 
patients aged ≥66 years (Lang et al., 2009), compared with $32,000 (age 65–69) and 
$28,000 (age 70–74) in our study. The higher cost in Lang et al. could potentially be 
attributed to different data sources and different methods for estimating cost in SEER-
Medicare and MEPS, and different methods computing lifetime costs.
As reported in this paper, achieving the HP2020 objective of reducing invasive CRC 
incidence by 15% by year 2020 would potentially save ~150,000 life-years and $624 million 
on healthcare costs. To achieve this objective may require implementing evidence-based 
single-or multi-component interventions recommended by the Community Preventive 
Services Task Force (Sabatino et al., 2012). These interventions such as client reminders, 
client incentives, one-on-one education, reducing out-of-pocket costs, reducing structural 
barriers, provider assessment and feedback, and provider incentive, have been found to be 
effective in increasing community demand, enhancing community access, and increasing 
provider delivery of recommended CRC screening services. The potential health benefits 
and substantial cost-savings reported in this paper can further encourage on-going efforts 
around implementing evidence-based interventions for CRC prevention and awareness that 
could aid in achieving the HP2020, or even HP2030 objective.
Furthermore, our results show that after reducing invasive CRC incidence rates by 15% for 
each group from 2007 to 2020, the aggregate potential LYs saved and cost-savings were 
highest among male, NHW, and age 60–64 population. These results can help inform 
adjustments to objectives to eliminate disparities between groups. For example, among the 
racial/ethnic groups, NHB had the highest baseline CRC incidence rate, followed by NHW 
and Hispanics (HP2020, 2014). Based on our results, a CRC prevention and control initiative 
targeting an additional 3–4% reduction (to the 15% reduction) for NHB would eliminate the 
gap in the aggregate LYs saved between NHB and Hispanics, and an additional 31–32% 
reduction would eliminate the gap between NHB and NHW.
CRC prevention and control initiatives include promoting healthy weight, physical activity, 
smoking cessation, reducing consumption of alcohol and red and processed meats, and 
increasing vitamin D intake (Moukayed and Grant, 2013; Mohr et al., 2015). These 
prevention activities are part of the CDC’s comprehensive cancer control program efforts to 
prevent CRC before it ever occurs (CDC, 2016a,b). CDC has also developed and 
implemented the Colorectal Cancer Control Program, which funds grantees in 23 states, 6 
universities and one tribe to promote population-wide CRC screening through the use of 
recommended evidence-based interventions described earlier. The program also strives to 
improve adherence to CRC screening and to assure timely and appropriate clinical 
preventive services and treatment (Henley et al., 2017; CDC, 2016a,b). Moreover, CDC has 
a long-running multimedia, multi-pronged national campaign to educate people about their 
CRC risks and to encourage age-eligible population to be screened (CDC, 2017a,b; 
Ekwueme et al., 2014). It is our belief that these CDC efforts will contribute to achieving the 
HP2020 CRC objective and the findings reported in this paper serve as approximations of 
the potential health benefits and cost-savings from these efforts.
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Our study has several strengths. First, stratified by sex, race/ethnicity, and age, our results 
provide data for cost-effectiveness analysis or budget impact analysis to evaluate CRC 
prevention programs at the subpopulation level. Second, the estimation of the survival curves 
is robust because the extrapolation beyond the follow-up is based on a validated method 
(Hwang and Wang, 1999). Last, our costs estimates were obtained from a nationally 
representative dataset, which covers a wide range of medical services and payers and 
includes survey participants at all ages.
Our study also has several limitations. As previously stated, we did not present groups 
whose 2007 incidence rates were lower than the HP2020 target objective of 39.9/100,000 
population. Such groups include American Indians or Alaska Natives, Asian/Pacific 
Islanders, and people aged < 50 years. However, some of the highest CRC incidence rates in 
the U.S. occur among American Indians or Alaska Natives populations in Alaska and the 
Northern and Southern Plains (Perdue et al., 2014). This study did not estimate the benefit of 
reducing CRC incidence in these populations. Our survival functions were estimated based 
on the existing data from 2001 to 2011. If recently developed treatment regimen which 
significantly improves survival outcomes for CRC patients is used as standard of care after 
2011, our estimates of LYs saved may be overestimated. However, lifetime healthcare cost-
savings can be either underestimated or overestimated, depending on how costly the new 
technology or treatment regimen will be. We assumed that annual cost associated with CRC 
was an average and therefore constant throughout their lifespan. However, CRC patients 
usually incur increased costs at later stages, which was not captured in our analyses. 
Nonetheless, this impact can be minimized by using average annual cost to compute the 
lifetime costs. Moreover, as aforementioned, our aggregate estimates are mainly driven by 
the assumption on a 15% reduction in the baseline CRC incidence rate for every group, 
which needs to be noted as a caveat when interpreting the aggregate estimates. Nonetheless, 
the percentage reduction can be changed based on the target aggregate LYs saved and 
lifetime cost-savings to implement CRC prevention and control programs and activities. Our 
analysis was also unable to capture the additional benefits of screening on early detection of 
CRC after 2011. Thus, we may have underestimated the health benefits and cost-savings. 
Last, we used relative survival rather than cause-specific survival to estimate life expectancy 
to avoid the potential bias from misclassification of CRC-specific cause of death and 
competing risks (Janssen-Heijnen et al., 2010; Nelson, 2017; Sarfati et al., 2010). However, 
we also recognize that using relative survival has its own bias, e.g., requiring detailed life 
tables of the comparison group (Hu et al., 2013), which does not apply to our study.
5. Conclusion
Reducing CRC incidence by 15% from 2007 to 2020 could have significant benefits for the 
nation in terms of potential LYs saved (~150,000 years) and lifetime healthcare cost-savings 
(~$624 million). Our results provide quantitative measures of the health and financial 
benefits of meeting the HP2020 objective for CRC incidence. This study framework can be 
used to assess future progress in improving health and economic outcomes of CRC.
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Fig. 1. 
A graphical illustration of per-person potential life years saved.
Dashed curve: survival function for a colorectal cancer (CRC) patient cohort.
Solid curve: survival function for the corresponding reference group.
Shaded area: the difference in life expectancies between a CRC group and the corresponding 
reference group.
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Fig. 2. 
A graphical illustration of per-person lifetime healthcare cost-savings.
Dotted curve: smoothed function of healthcare cost associated with colorectal cancer (CRC) 
in present value.
Dashed curve: survival function for a CRC group.
Solid curve: expected cost in present value.
Shaded area: per-person lifetime health care cost savings.
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Table 3
Per-person lifetime cost-savings and aggregate cost-savings if the Healthy People (HP) 2020 target of reducing 
invasive colorectal cancer (CRC) by 15% for each group were achieved.a
Per-person lifetime cost- savingsb (2013$) (SE) Aggregate lifetime cost-savingsc (million, 2013$)
Total – 623.5
Sex*
 Male 24,000 (24) 329.3
 Female 28,000 (30) 294.2
Race/ethnicity*
 Non-Hispanic White 27,000 (23) 371.1
 Non-Hispanic Black 23,000 (42) 80.8
 Hispanic 26,000 (47) 102.5
Age group (years)*
 50–54 46,000 (68) 79.8
 55–59 45,000 (70) 111.5
 60–64 43,000 (68) 143.9
 65–69 32,000 (59) 142.7
 70–74 28,000 (53) 129.7
 75–79 22,000 (53) 88.9
 80+ 15,000 (30) 100.0
SE, standard error.
aAll healthcare costs were adjusted to 2013 dollars using the Personal Health Care Expenditure Price Index. CRC status, age, sex, race, education, 
marital status, number of comorbid conditions, health insurance, and census region were controlled for in the two-part model.
bSee Section 2.5 for the calculation of per-person lifetime cost-savings.
cAggregate cost-savings were calculated by multiplying the estimated reduction in the number of CRC patients with per-person lifetime cost-
savings.
*p < 0.05 comparing statistically significant difference in per-person lifetime cost savings among sex, race/ethnicities and age groups.
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